PRIME MEDICINE INC
PRME · NASDAQ
Updated at 2026-10-14 08:52:42
- Today's High
- $3.61
- Today’s Low
- $3.27
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $3.95
- Previous Close
- $3.61
- Volume
- 3.13M
- Market Cap
- $654.77M
- P/E Ratio
- --
- EPS
- $-1.09
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 60 FIRST STREET, CAMBRIDGE, MA, UNITED STATES, 02141
- Country
- US
- Listing Date
- 2022-10-20
- Fiscal Year End
- December
- Shares Outstanding
- 180.62M
- CIK
- 0001894562
- Website
- primemedicine.com
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA modifications. The firm has curated a diverse pipeline targeting severe diseases, including genetic disorders and various cancers, addressing substantial unmet medical needs within the healthcare system. With a strong intellectual property foundation and a commitment to developing innovative therapeutic solutions, Prime Medicine is strategically positioned for notable growth and has the potential to significantly change therapeutic approaches in the biopharmaceutical industry.
Financial Metrics
Revenue
2026-06-30
$1.15M
2026-03-31
$856K
2025-12-31
$838K
2025-09-30
$1.22M
Operating Expenses
2026-06-30
$44.43M
2026-03-31
$49.65M
2025-12-31
$49.44M
2025-09-30
$11.2M
Net Income
2026-06-30
-$42.1M
2026-03-31
-$49.12M
2025-12-31
-$46.07M
2025-09-30
-$50.58M
Net Profit Margin
2026-06-30
-3.64K%
2026-03-31
-5.73K%
2025-12-31
-5.49K%
2025-09-30
-4.12K%
Earnings Per Share
2026-06-30
$-0.24
2026-03-31
$-0.28
2025-12-31
$-0.24
2025-09-30
$-0.32
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$40.32M
2026-03-31
-$47.26M
2025-12-31
-$44.2M
2025-09-30
-$48.7M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $1.15M | $856K | $838K | $1.22M |
| Operating Expenses | $44.43M | $49.65M | $49.44M | $11.2M |
| Net Income | -$42.1M | -$49.12M | -$46.07M | -$50.58M |
| Net Profit Margin | -3.64K% | -5.73K% | -5.49K% | -4.12K% |
| Earnings Per Share | $-0.24 | $-0.28 | $-0.24 | $-0.32 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$40.32M | -$47.26M | -$44.2M | -$48.7M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.